<DOC>
	<DOC>NCT00868413</DOC>
	<brief_summary>This is a Phase 1 study evaluating the safety of ABT-263 administered in combination with either FCR or BR in subjects with relapsed or refractory chronic lymphocytic leukemia.</brief_summary>
	<brief_title>Study of ABT-263 When Administered in Combination With Either Fludarabine/Cyclophosphamide/Rituximab or Bendamustine/Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia, Lymphoid</mesh_term>
	<mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Bendamustine Hydrochloride</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Navitoclax</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<criteria>Must have relapsed or refractory Chronic Lymphocytic Leukemia (CLL), received no more than 5 prior myelosuppressive/chemotherapy regimens and must be a candidate for treatment with either Fludarabine/Cyclophosphamide/Rituximab (FCR) or Bendamustine/Rituximab (BR); Subject has an Eastern Cooperative Oncology Group (ECOG) performance score of &lt;/=1; Must have adequate bone marrow independent of growth factor support (with the exception of subjects with bone marrow heavily infiltrated with underlying disease [80% or more] who may use growth factor support to achieve Absolute Neutrophil Count (ANC) eligibility criteria), per local laboratory reference range at Screening as follows: ANC &gt;/=1000/mcL, Platelets&gt;/= 100,000/mm3 (entry platelet count must be independent of transfusion within 14 days of Screening),Hemoglobin &gt;/= 9.0 g/dL. Subject has history or is clinically suspicious for cancerrelated Central Nervous System disease; Has history of severe allergic or anaphylactic reactions to human, humanized, chimeric or murine monoclonal antibodies; Has undergone an allogeneic stem cell transplant; Exhibits evidence of other uncontrolled condition(s) including, but not limited to: uncontrolled systemic infection, diagnosis of fever and neutropenia within 1 week prior to study drug administration; Has underlying, predisposing condition of bleeding or currently exhibits signs of bleeding; Has a recent history of nonchemotherapy induced thrombocytopenic associated bleeding; Currently receiving or requires anticoagulation therapy; Has active immune thrombocytopenic purpura (ITP) or a history of being refractory to platelet transfusions (within 1 year prior to 1st dose of study drug); Has active peptic ulcer disease or other hemorrhagic esophagitis/gastritis.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2013</verification_date>
</DOC>